Novartis Drug Patent Portfolio

Novartis owns 53 orange book drugs protected by 286 US patents with Alomide having the least patent protection, holding only 1 patent. And Promacta with maximum patent protection, holding 28 patents. Given below is the list of Novartis's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11951101 Methods of using factor B inhibitors 15 Jul, 2041
Active
US11603363 Crystalline form of LNP023 25 May, 2041
Active
US11407735 Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide 14 May, 2040
Active
US11504333 Pharmaceutical composition 29 Dec, 2038
Active
US11723901 Uses of piperidinyl-indole derivatives 30 Aug, 2038
Active
US11504333 Pharmaceutical composition 29 Jun, 2038
Active
US10722471 Galenic formulations of organic compounds 02 Feb, 2037
Active
US10851377 Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder 25 Aug, 2036
Active
US11944602 Treatment of autoimmune disease in a patient receiving additionally a beta-blocker 24 Jul, 2036
Active
US10799506 Ribociclib tablet 14 Apr, 2036
Active
US12064434 Ribociclib tablet 14 Apr, 2036
Active
US12109277 09 Mar, 2036
Active
US11951190 Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer 12 Nov, 2035
Active
US10398791 Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer 17 Oct, 2034
Active
US10125369 PCSK9 iRNA compositions and methods of use thereof 18 Aug, 2034
Active
US10093663 Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof 14 Jul, 2034
Active
US9682968 Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof 14 Jul, 2034
Active
US10869869 Method of adjuvant cancer treatment 02 Mar, 2034
Active
US10869869 Method of adjuvant cancer treatment 30 Aug, 2033
Active
US8829195 Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 13 May, 2033
Active
US8227462 Pyrrolidine-1,2-dicarboxamide derivatives 29 Apr, 2033
Active
US9061029 Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity 07 Oct, 2032
Active
US9592208 Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol 30 Sep, 2032
Active
US8580304 Pharmaceutical composition 28 Jul, 2032
Active
US9155706 Pharmaceutical composition 28 Jul, 2032
Active
US9271941 Pharmaceutical composition 28 Jul, 2032
Active
US9399021 Pharmaceutical composition 28 Jul, 2032
Active
US9061029 Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity 07 Apr, 2032
Active
US9592208 Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol 30 Mar, 2032
Active
US8703787 Methods of using ALK inhibitors 02 Feb, 2032
Active
US8580304 Pharmaceutical composition 28 Jan, 2032
Active
US9155706 Pharmaceutical composition 28 Jan, 2032
Active
US9271941 Pharmaceutical composition 28 Jan, 2032
Active
US9399021 Pharmaceutical composition 28 Jan, 2032
Active
US9309229 Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine 18 Jan, 2032
Active
US12071402 Immunosuppressant formulations 05 Jan, 2032
Active
US9193732 Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof 09 Nov, 2031
Active
US9868739 Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof 09 Nov, 2031
Active
US8703781 Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors 15 Apr, 2031
Active
US8952018 Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors 15 Apr, 2031
Active
US8415355 Pyrrolopyrimidine compounds and their uses 13 Mar, 2031
Active
US8575146 Pharmaceutical uses of staurosporine derivatives 02 Dec, 2030
Active
US8492441 Dosage regimen of an S1P receptor agonist 30 Nov, 2030
Active
US8703781 Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors 15 Oct, 2030
Active
US8952018 Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors 15 Oct, 2030
Active
US7994185 Benzene sulfonamide thiazole and oxazole compounds 20 Jul, 2030
Active
US8415345 Benzene sulfonamide thiazole and oxazole compounds 20 Jul, 2030
Active
US8039474 2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists 29 Jun, 2030
Active
US8039479 Compounds and compositions as protein kinase inhibitors 29 Jun, 2030
Active
US8685980 Pyrrolopyrimidine compounds and their uses 25 May, 2030
Active
US7994185 Benzene sulfonamide thiazole and oxazole compounds 20 Jan, 2030
Active
US8415345 Benzene sulfonamide thiazole and oxazole compounds 20 Jan, 2030
Active
US8613949 Galenical formulations of organic compounds 21 Dec, 2029
Active
US8106022 Carbohydrate conjugates as delivery agents for oligonucleotides 12 Dec, 2029
Active
US8962630 Pyrrolopyrimidine compounds and their uses 09 Dec, 2029
Active
US9233956 Benzene sulfonamide thiazole and oxazole compounds 04 Nov, 2029
Active
US8178582 Pharmaceutical compositions having desirable bioavailability 10 Oct, 2029
Active
US8722735 Pharmaceutical compositions having desirable bioavailability 10 Oct, 2029
Active
US8821927 Pharmaceutical composition 18 Sep, 2029
Active
US8476268 Pyrrolidine-1,2-dicarboxamide derivatives 10 Sep, 2029
Active
US9416136 Pyrrolopyrimidine compounds and their uses 20 Aug, 2029
Active
US8754123 Pharmaceutical compositions having desirable bioavailability 19 May, 2029
Active
US9233956 Benzene sulfonamide thiazole and oxazole compounds 04 May, 2029
Active
US9144561 Pharmaceutical compositions having desirable bioavailability 13 Mar, 2029
Active
US8163904 Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide 23 Feb, 2029
Active
US10806791 Carbohydrate conjugates as delivery agents for oligonucleotides 04 Dec, 2028
Active
US8828956 Carbohydrate conjugates as delivery agents for oligonucleotides 04 Dec, 2028
Active
US9370582 Carbohydrate conjugates as delivery agents for oligonucleotides 04 Dec, 2028
Active
US8182838 Dry powder composition comprising co-jet milled particles for pulmonary inhalation 20 Oct, 2028
Active
US8479730 Inhaler device 11 Oct, 2028
Active
US7973031 Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity 09 Oct, 2028
Active
US7939519 Immunosuppresant compounds and compositions 27 Aug, 2028
Active
US10131907 Glycoconjugates of RNA interference agents 24 Aug, 2028
Active
US8163904 Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide 23 Aug, 2028
Active
US11369590 PSMA binding ligand-linker conjugates and methods for using 15 Aug, 2028
Active
US10406240 PSMA binding ligand-linker conjugates and methods for using 15 Aug, 2028
Active
US11318121 PSMA binding ligand-linker conjugates and methods for using 15 Aug, 2028
Active
US9006224 Neuroendocrine tumor treatment 01 Jul, 2028
Active
US8324225 Pyrrolopyrimidine compounds and their uses 17 Jun, 2028
Active
US7964592 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders 29 Apr, 2028
Active
US8293756 Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate 25 Mar, 2028
Active
US7932241 Pharmaceutical products comprising bisphosphonates 05 Feb, 2028
Active
US8052993 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) 01 Feb, 2028
Active
US8052994 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) 01 Feb, 2028
Active
US8052995 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) 01 Feb, 2028
Active
US8062665 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) 01 Feb, 2028
Active
US8071129 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) 01 Feb, 2028
Active
US8828430 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) 01 Feb, 2028
Active
US8222222 Compositions and methods for inhibiting expression of the PCSK9 gene 29 Dec, 2027
Active
US10543179 Dosage regimen of an S1P receptor modulator 25 Dec, 2027
Active
US9187405 S1P receptor modulators for treating relasping-remitting multiple sclerosis 25 Dec, 2027
Active
US7378423 Pyrimidine compound and medical use thereof 29 Nov, 2027
Active
US8377921 Compounds and compositions as protein kinase inhibitors 20 Nov, 2027
Active
US8399450 Compounds and compositions as protein kinase inhibitors 20 Nov, 2027
Active
US8293756 Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate 25 Sep, 2027
Active
US8052993 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) 01 Aug, 2027
Active
US8052994 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) 01 Aug, 2027
Active
US8052995 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) 01 Aug, 2027
Active
US8062665 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) 01 Aug, 2027
Active
US8071129 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) 01 Aug, 2027
Active
US8828430 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) 01 Aug, 2027
Active
US9187405 S1P receptor modulators for treating relasping-remitting multiple sclerosis 25 Jun, 2027
Active
US7378423 Pyrimidine compound and medical use thereof 29 May, 2027
Active
US8877938 Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations 27 May, 2027
Active
US8809292 Compositions and methods for inhibiting expression of the PCSK9 gene 10 May, 2027
Active
US8389537 Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide 18 Jan, 2027
Active
US8415363 Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide 18 Jan, 2027
Active
US8501760 Pharmaceutical compositions comprising nilotinib or its salt 18 Jan, 2027
Active
US9388134 Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations 08 Nov, 2026
Active
US8324283 Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol 29 Sep, 2026
Active
US8389537 Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide 18 Jul, 2026
Active
US8415363 Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide 18 Jul, 2026
Active
US8501760 Pharmaceutical compositions comprising nilotinib or its salt 18 Jul, 2026
Active
US8168616 Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension 03 Jul, 2026
Active
US8410131 Cancer treatment 01 May, 2026
Active
US7893074 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders 25 Apr, 2026
Active
US8324283 Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol 29 Mar, 2026
Active
US7547719 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) 13 Jan, 2026
Active
US8835443 Pyrimidine compound and medical use thereof 10 Dec, 2025
Active
US8324189 Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases 29 Nov, 2025
Active
US8410131 Cancer treatment 01 Nov, 2025
Active
US7547719 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) 13 Jul, 2025
Active
US8835443 Pyrimidine compound and medical use thereof 10 Jun, 2025
Active
US8324189 Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases 29 May, 2025
Active
US6878721 Beta2-adrenoceptor agonists 25 Feb, 2025
Active
US8101659 Methods of treatment and pharmaceutical composition 15 Jan, 2025
Active
US11530408 Therapeutic compositions 18 May, 2024 Expired
US10273477 Therapeutic compositions 08 Mar, 2024 Expired
US10669544 Therapeutic compositions 08 Mar, 2024 Expired
US9708615 Therapeutic compositions 08 Mar, 2024 Expired
US7169791 Inhibitors of tyrosine kinases 04 Jan, 2024 Expired
US9708610 Compositions comprising alternating 2′-modified nucleosides for use in gene modulation 01 Jan, 2024 Expired
US7795293 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) 21 Nov, 2023 Expired
US8475839 Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same 16 Nov, 2023 Expired
US10266825 Compositions comprising alternating 2′-modified nucleosides for use in gene modulation 04 Nov, 2023 Expired
US11078485 Compositions comprising alternating 2′-modified nucleosides for use in gene modulation 04 Nov, 2023 Expired
US7105530 Pyrimidineamines as angiogenesis modulators 19 Oct, 2023 Expired
US7589079 Crystalline and amorphous forms of beta-L-2′-deoxythymidine 11 Sep, 2023 Expired
US7858594 Crystalline and amorphous forms of beta-L-2′-deoxythymidine 11 Sep, 2023 Expired
US7977376 Olopatadine formulations for topical nasal administration 02 Aug, 2023 Expired
US7169791 Inhibitors of tyrosine kinases 04 Jul, 2023 Expired
US7795293 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) 21 May, 2023 Expired
US7160870 Thrombopoietin mimetics 20 May, 2023 Expired
US8183295 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic 16 May, 2023 Expired
US8101599 Pharmaceutical composition containing anti-hypertensive agents 16 May, 2023 Expired
US8475839 Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same 16 May, 2023 Expired
US8399508 Olopatadine formulations for topical nasal administration 17 Mar, 2023 Expired
US8232383 RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) 20 Feb, 2023 Expired
US7977376 Olopatadine formulations for topical nasal administration 02 Feb, 2023 Expired
US8188276 2,4-pyrimidinediamine compounds and their uses 31 Jan, 2023 Expired
US8835430 2,4-pyrimidinediamine compounds and their uses 31 Jan, 2023 Expired
US9018204 2,4-pyrimidinediamine compounds and their uses 31 Jan, 2023 Expired
US9416112 2,4-pyrimidinediamine compounds and their uses 31 Jan, 2023 Expired
US7160870 Thrombopoietin mimetics 20 Nov, 2022 Expired
US8222244 Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity 29 Oct, 2022 Expired
US8399508 Olopatadine formulations for topical nasal administration 17 Sep, 2022 Expired
US8436010 Treatment of solid tumors with rapamycin derivatives 22 Aug, 2022 Expired
US8778962 Treatment of solid tumors with rapamycin derivatives 18 Aug, 2022 Expired
US10590418 Methods and compositions for RNAi mediated inhibition of gene expression in mammals 19 Jul, 2022 Expired
US6958335 Treatment of gastrointestinal stromal tumors 19 Jun, 2022 Expired
US8546143 Compositions and methods for inhibiting expression of a target gene 23 Apr, 2022 Expired
US9074213 Compositions and methods for inhibiting expression of a target gene 09 Mar, 2022 Expired
US8436010 Treatment of solid tumors with rapamycin derivatives 22 Feb, 2022 Expired
US8778962 Treatment of solid tumors with rapamycin derivatives 18 Feb, 2022 Expired
US6958335 Treatment of gastrointestinal stromal tumors 19 Dec, 2021 Expired
US7262203 Pyrimidineamines as angiogenesis modulators 19 Dec, 2021 Expired
US8114885 Chemical compounds 19 Dec, 2021 Expired
US7332481 Thrombopoietin mimetics 24 Nov, 2021 Expired
US7452874 Thrombopoietin mimetics 24 Nov, 2021 Expired
US7473686 Thrombopoietin mimetics 24 Nov, 2021 Expired
US7790704 Thrombopoietin mimetics 24 Nov, 2021 Expired
US7157466 Quinazoline ditosylate salt compounds 19 Nov, 2021 Expired
US8618174 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases 15 Nov, 2021 Expired
US7736670 Method of making particles for use in a pharmaceutical composition 27 Jun, 2021 Expired
US8048451 Pharmaceutical compositions for inhalation 27 Jun, 2021 Expired
US8303991 Method of making particles for use in a pharmaceutical composition 27 Jun, 2021 Expired
US8435567 Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation 27 Jun, 2021 Expired
US8580306 Particles for use in a pharmaceutical composition 27 Jun, 2021 Expired
US8956661 Method of making composite particles for use in pharmaceutical compositions and composite particles and compositions thereof 27 Jun, 2021 Expired
US9931304 Method of making particles for use in a pharmaceutical composition 27 Jun, 2021 Expired
US9962338 Method of making particles for use in a pharmaceutical composition 27 Jun, 2021 Expired
US8119148 Suspension comprising oxcarbazepine 19 Jun, 2021 Expired
US7332481 Thrombopoietin mimetics 24 May, 2021 Expired
US7452874 Thrombopoietin mimetics 24 May, 2021 Expired
US7473686 Thrombopoietin mimetics 24 May, 2021 Expired
US7790704 Thrombopoietin mimetics 24 May, 2021 Expired
US7229607 Treatment of respiratory disease 09 Apr, 2021 Expired
US8029768 Treatment of respiratory diseases 09 Apr, 2021 Expired
US7153964 Pyrimidine compounds 26 Feb, 2021 Expired
US8119148 Suspension comprising oxcarbazepine 19 Dec, 2020 Expired
US6887459 Aerosol composition comprising formoterol 28 Nov, 2020 Expired
US6569837 β-L-2′-deoxy pyrimidine nucleosides for the treatment of hepatitis B 25 Oct, 2020 Expired
US6713485 Heterocyclic compounds 29 Sep, 2020 Expired
US6559188 Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes 15 Sep, 2020 Expired
US6878749 Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes 15 Sep, 2020 Expired
US7297703 Macrolides 06 Jun, 2020 Expired
US8067437 Beta-2-adrenoreceptor agonists 02 Jun, 2020 Expired
US8658673 BETA2-adrenoreceptor agonists 02 Jun, 2020 Expired
US8796307 Beta2-adrenoreceptor agonists 02 Jun, 2020 Expired
US7820694 Beta-2-adrenoreceptor agonists 02 Jun, 2020 Expired
US8283362 Beta-2-adrenoreceptor agonists 02 Jun, 2020 Expired
US5665772 O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants 09 Mar, 2020 Expired
US7297703 Macrolides 06 Dec, 2019 Expired
US7741338 Macrolides 06 Dec, 2019 Expired
US6894051 Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use 23 Nov, 2019 Expired
US5665772 O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants 09 Sep, 2019 Expired
US5604229 2-amino-1,3-propanediol compound and immunosuppressant 18 Aug, 2019 Expired
US6395716 β-L-2′-deoxy-nucleosides for the treatment of hepatitis B 10 Aug, 2019 Expired
US6444652 β-L-2'-deoxy-nucleosides for the treatment of hepatitis B 10 Aug, 2019 Expired
US6566344 β-L-2′-deoxy-nucleosides for the treatment of hepatitis B 10 Aug, 2019 Expired
US7795238 β-L-2′-deoxy-nucleosides for the treatment of hepatitis B 10 Aug, 2019 Expired
US7544799 Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use 16 Jul, 2019 Expired
USRE43932 Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use 16 Jul, 2019 Expired
US6395728 Method of treatment and pharmaceutical composition 08 Jul, 2019 Expired
US6894051 Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use 23 May, 2019 Expired
US6280959 Metal complexes 30 Apr, 2019 Expired
US6465504 Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators 05 Apr, 2019 Expired
US6488027 Powder inhaler 08 Mar, 2019 Expired
US5604229 2-amino-1,3-propanediol compound and immunosuppressant 18 Feb, 2019 Expired
US7544799 Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use 16 Jan, 2019 Expired
USRE43932 Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use 16 Jan, 2019 Expired
US6727256 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors 08 Jan, 2019 Expired
US8513262 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors 08 Jan, 2019 Expired
US6280959 Metal complexes 30 Oct, 2018 Expired
US7037525 Oxacarbazepine film-coated tablets 12 Aug, 2018 Expired
US5559111 δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides 21 Jul, 2018 Expired
US6528678 Phosgene-free process for preparing carbamates 24 Apr, 2018 Expired
US6582678 Carrier particles for use in dry powder inhalers 24 Apr, 2018 Expired
US6306900 Enteric coated pharmaceutical compositions 27 Feb, 2018 Expired
US7037525 Oxacarbazepine film-coated tablets 12 Feb, 2018 Expired
US6239124 Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin 11 Feb, 2018 Expired
US6455518 Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin 29 Jan, 2018 Expired
US6294197 Solid oral dosage forms of valsartan 18 Dec, 2017 Expired
US6641841 Tablet composition 14 Nov, 2017 Expired
US6844008 Tablet composition 14 Nov, 2017 Expired
US6004565 Compositions and methods of using compositions with accelerated lymphocyte homing immunosuppressive properties 23 Sep, 2017 Expired
US6239124 Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin 11 Aug, 2017 Expired
US6455518 Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin 29 Jul, 2017 Expired
US6391874 Fused heterocyclic compounds as protein tyrosine kinase inhibitors 11 Jul, 2017 Expired
US6828320 Heterocyclic compounds 11 Jul, 2017 Expired
US6596750 Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators 24 Jun, 2017 Expired
US6294197 Solid oral dosage forms of valsartan 18 Jun, 2017 Expired
US5972990 Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims 26 Apr, 2017 Expired
US6025391 Enteric-coated pharmaceutical compositions of mycophenolate 10 Apr, 2017 Expired
US6172107 Entric-coated pharmaceutical compositions 10 Apr, 2017 Expired
US5922338 Polyol esters, their preparation and use in depot forms of pharmacologically active agents 13 Jan, 2017 Expired
US5922682 Polyol esters, their preparation and use in depot forms of pharmacologically active agents 13 Jan, 2017 Expired
US6004973 Pharmaceutical compositions comprising rafamycin coprecipitates 12 Jan, 2017 Expired
US5972990 Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims 26 Oct, 2016 Expired
US5922338 Polyol esters, their preparation and use in depot forms of pharmacologically active agents 13 Jul, 2016 Expired
US5922682 Polyol esters, their preparation and use in depot forms of pharmacologically active agents 13 Jul, 2016 Expired
US6004973 Pharmaceutical compositions comprising rafamycin coprecipitates 12 Jul, 2016 Expired
US5840763 Treatment of a latent infection of herpes viruses 01 Mar, 2016 Expired
US5916893 Treatment of a latent infection of herpes virus 01 Mar, 2016 Expired
US6521260 Carrier particles for use in dry powder inhalers 31 Jan, 2016 Expired
US5753618 Somatostatin analogue composition and use in treating breast cancer 19 Nov, 2015 Expired
US5840763 Treatment of a latent infection of herpes viruses 01 Sep, 2015 Expired
US5916893 Treatment of a latent infection of herpes virus 01 Sep, 2015 Expired
US5521184 Pyrimidine derivatives and processes for the preparation thereof 04 Jul, 2015 Expired
US5753618 Somatostatin analogue composition and use in treating breast cancer 19 May, 2015 Expired
US5688530 Sustained release formulations of water soluble peptides 18 May, 2015 Expired
US5866581 Penciclovir for the treatment of post therapeutic neuralgia 04 Apr, 2015 Expired
US6124304 Penciclovir for the treatment of zoster associated pain 04 Apr, 2015 Expired
US5521184 Pyrimidine derivatives and processes for the preparation thereof 04 Jan, 2015 Expired
US5639480 Sustained release formulations of water soluble peptides 17 Dec, 2014 Expired
US5688530 Sustained release formulations of water soluble peptides 18 Nov, 2014 Expired
US5677331 Antimalarial compositions 14 Oct, 2014 Expired
US5866581 Penciclovir for the treatment of post therapeutic neuralgia 04 Oct, 2014 Expired
US6124304 Penciclovir for the treatment of zoster associated pain 04 Oct, 2014 Expired
US5985321 Soft gelatin capsule manufacture 26 Sep, 2014 Expired
US5639480 Sustained release formulations of water soluble peptides 17 Jun, 2014 Expired
US6440990 O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants 24 Mar, 2014 Expired
US5602176 Phenyl carbamate 11 Feb, 2014 Expired
US5538739 Sustained release formulations of water soluble peptides 23 Jan, 2014 Expired
US5441958 Ophthalmic compositions comprising emedastine and methods for their use 08 Dec, 2013 Expired
US6440990 O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants 24 Sep, 2013 Expired
US5538739 Sustained release formulations of water soluble peptides 23 Jul, 2013 Expired
US4939130 Substituted alkanediphosphonic acids and pharmaceutical use 02 Mar, 2013 Expired
US5488150 Crystals of N-(trans-4-isopropylcyclohexycarbonyl)-D-phenylalanine and methods for preparing them 30 Jan, 2013 Expired
US5463116 Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them 21 Oct, 2012 Expired
US5457126 Use of lodoxamide to treat ophthalmic allergic conditions 10 Oct, 2012 Expired
US5399578 Acyl compounds 21 Sep, 2012 Expired
US4939130 Substituted alkanediphosphonic acids and pharmaceutical use 02 Sep, 2012 Expired
US5442049 Oligonucleotides for modulating the effects of cytomegalovirus infections 15 Aug, 2012 Expired
US5595978 Composition and method for treatment of CMV retinites 15 Aug, 2012 Expired
US4948807 Phenyl carbamates 14 Aug, 2012 Expired


Given below is the list of recent legal activities going on the following drug patents of Novartis.

Activity Date Patent Number
Patent litigations
Expire Patent 01 Jul, 2024 US8188276 (Litigated)
Maintenance Fee Reminder Mailed 24 Jun, 2024 US8303991 (Litigated)
Expire Patent 24 Jun, 2024 US8183295
Maintenance Fee Reminder Mailed 24 Jun, 2024 US8303991 (Litigated)
Surcharge for Late Payment, Large Entity 11 Jun, 2024 US10806791
Payment of Maintenance Fee, 4th Year, Large Entity 11 Jun, 2024 US10806791
Maintenance Fee Reminder Mailed 10 Jun, 2024 US10806791
Payment of Maintenance Fee, 4th Year, Large Entity 05 Jun, 2024 US10869869
Payment of Maintenance Fee, 4th Year, Large Entity 03 Jun, 2024 US10851377
Expire Patent 03 Jun, 2024 US8168616
Maintenance Fee Reminder Mailed 27 May, 2024 US8283362
Payment of Maintenance Fee, 12th Year, Large Entity 22 May, 2024 US8324189
Payment of Maintenance Fee, 12th Year, Large Entity 22 May, 2024 US8324225
Payment of Maintenance Fee, 12th Year, Large Entity 22 May, 2024 US8324225
Expire Patent 22 Apr, 2024 US10590418


Novartis's Drug Patent Litigations

Novartis's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 05, 1995, against patent number US5922682. The petitioner , challenged the validity of this patent, with BRICH et al as the respondent. Click below to track the latest information on how companies are challenging Novartis's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8101659 August, 2020 Terminated-Denied
(16 Feb, 2021)
Novartis Pharmaceuticals Corporation Biocon Pharma Limited
US9006224 July, 2016 Final Written Decision
(05 Oct, 2020)
Novartis AG Par Pharmaceutical, Inc. et al.
US8410131 June, 2017 Terminated-Settled
(03 Jun, 2019)
Novartis Pharmaceuticals Corporation Breckenridge Pharmaceutial, Inc.
US8410131 January, 2018 Terminated-Settled
(03 Jun, 2019)
Novartis Pharmaceuticals Corporation Hikma Pharmaceuticals PLC
US9187405 August, 2017 FWD Entered
(07 Aug, 2018)
Novartis Pharmaceuticals Corporation Actavis Elizabeth LLC
US9187405 August, 2017 Terminated
(07 Aug, 2018)
Novartis Pharmaceuticals Corporation Sun Pharmaceutical Industries, Ltd. et al.
US9187405 February, 2017 FWD Entered
(11 Jul, 2018)
Novartis AG Apotex Inc.
US5665772 October, 2015 FWD Entered
(11 Jan, 2018)
Novartis AG Par Pharmaceutical, Inc.
US9006224 March, 2017 Final Written Decision
(25 Sep, 2017)
Novartis AG Argentum Pharmaceuticals LLC et al.
US9006224 March, 2017 Terminated-Settled
(25 Sep, 2017)
Novartis AG West-Ward Pharmaceuticals International Limited
US9187405 June, 2017 FWD Entered
(17 Aug, 2017)
Novartis AG Argentum Pharmaceuticals LLC
US9006224 July, 2016 Terminated-Denied
(13 Feb, 2017)
Novartis AG Roxane Laboratories, Inc.
US5665772 May, 2016 FWD Entered
(27 Oct, 2016)
Novartis AG BRECKENRIDGE PHARMACEUTICAL, INC.
US5665772 May, 2016 Terminated-Denied
(27 Oct, 2016)
Novartis AG Par Pharmaceutical, Inc.
US5665772 May, 2016 FWD Entered
(27 Oct, 2016)
Novartis AG Roxane Laboratories, Inc.
US5665772 May, 2016 Terminated-Denied
(27 Oct, 2016)
Novartis AG Breckenridge Pharmaceutical, Inc.
US6455518 October, 2015 Terminated-Denied
(28 Apr, 2016)
Novartis AG Par Pharmaceutical, Inc.
US7297703 October, 2015 Terminated-Denied
(01 Apr, 2016)
Novartis AG Par Pharmaceutical, Inc.
US7741338 October, 2015 Terminated-Denied
(01 Apr, 2016)
Novartis AG Par Pharmaceutical, Inc.
US8324283 May, 2014 FWD Entered
(24 Sep, 2015)
Novartis AG TORRENT PHARMACEUTICALS LIMITED
US8324283 December, 2014 Final Written Decision
(24 Sep, 2015)
Novartis AG et al. Apotex, Inc. et al.
US10590418 April, 2012 Decision
(04 Mar, 2015)
Mark A. Kay et al
US8575146 January, 2011 Decision
(22 Mar, 2013)
Steven Coutre
US6894051 March, 2003 Decision
(24 Nov, 2003)
JURG ZIMMERMANN et al
US5972990 January, 1 Decision
(12 Feb, 1999)
PFEFFER et al
US5922682 April, 1995 Decision
(04 Jul, 1776)
BRICH et al


Novartis Drug Patents' Oppositions Filed in EPO

Novartis drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 20, 2003, by Sirna Therapeutics, Inc.. This opposition was filed on patent number EP00910510A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP15177166A May, 2023 Synthon BV Granted and Under Opposition
EP19174594A May, 2023 Brand Murray Fuller LLP Granted and Under Opposition
EP15177166A May, 2023 Wuesthoff & Wuesthoff Patentanwälte PartG mbB Granted and Under Opposition
EP19174594A May, 2023 STADA Arzneimittel AG Granted and Under Opposition
EP15177166A Mar, 2023 neuraxpharm Arzneimittel GmbH Granted and Under Opposition
EP15177166A Jan, 2023 Dr. Schön, Neymeyr & Partner Patentanwälte mbB Granted and Under Opposition
EP15177166A Jan, 2023 BIOGARAN Granted and Under Opposition
EP15177166A Jan, 2023 STADA Arzneimittel AG Granted and Under Opposition
EP18155722A Jan, 2023 Generics [UK] Limited Granted and Under Opposition
EP18155722A Jan, 2023 Ethypharm Granted and Under Opposition
EP18155722A Jan, 2023 STADA Arzneimittel AG Granted and Under Opposition
EP15177166A Jan, 2023 Bausch Health Ireland Limited Granted and Under Opposition
EP15177166A Dec, 2022 Vivanta Generics s.r.o. / MSN Labratories Private Ltd. Granted and Under Opposition
EP15177166A Dec, 2022 Heumann Pharma GmbH & Co. Generica KG Granted and Under Opposition
EP15177166A Dec, 2022 Accord Healthcare Ltd Granted and Under Opposition
EP15177166A Nov, 2022 A-med GmbH Granted and Under Opposition
EP15177166A Nov, 2022 RAFARM S.A. Granted and Under Opposition
EP15177166A Nov, 2022 Genepharm S.A. Granted and Under Opposition
EP15177166A Oct, 2022 Elpen Pharmaceutical Co. Inc. Granted and Under Opposition
EP15177166A Oct, 2022 Glenmark Pharmaceuticals Europe Ltd. Granted and Under Opposition
EP15177166A Oct, 2022 Teva Pharmaceutical Industries Ltd Granted and Under Opposition
EP15177166A Oct, 2022 Generics [UK] Limited Granted and Under Opposition
EP15177166A Oct, 2022 Zentiva k.s. Granted and Under Opposition
EP15177166A Oct, 2022 PHARMATHEN S.A. Granted and Under Opposition
EP13835019A Jun, 2022 Generics [UK] Limited Granted and Under Opposition
EP13835019A Jun, 2022 Teva Pharmaceutical Industries Ltd Granted and Under Opposition
EP13835019A Jun, 2022 STADA Arzneimittel AG Granted and Under Opposition
EP10176094A Apr, 2021 Alfred E. Tiefenbacher (GmbH & Co. KG) Granted and Under Opposition
EP10176094A Apr, 2021 betapharm Arzneimittel GmbH Granted and Under Opposition
EP10176094A Apr, 2021 Krka, d.d., Novo mesto Granted and Under Opposition
EP10176094A Apr, 2021 ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. Granted and Under Opposition
EP10176094A Apr, 2021 STADA Arzneimittel AG Granted and Under Opposition
EP10176094A Apr, 2021 D Young & Co LLP Granted and Under Opposition
EP10176094A Apr, 2021 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Granted and Under Opposition
EP11849974A Apr, 2021 Generics [UK] Limited Granted and Under Opposition
EP11849974A Apr, 2021 Teva Pharmaceutical Industries Ltd Granted and Under Opposition
EP10176094A Jan, 2021 Generics [UK] Limited Granted and Under Opposition
EP08798020A Jul, 2020 Boult Wade Tennant LLP Revoked
EP08798020A Jul, 2020 Orano Med Revoked
EP18155724A Jun, 2020 ARROW GENERIQUES Granted and Under Opposition
EP18155724A May, 2020 Teva Pharmaceutical Industries Ltd. Granted and Under Opposition
EP18155724A May, 2020 Zentiva k.s. Granted and Under Opposition
EP18155724A May, 2020 Generics [UK] Ltd Granted and Under Opposition
EP18155724A Apr, 2020 PUREN Pharma GmbH & Co. KG Granted and Under Opposition
EP10824148A Mar, 2020 Generics (UK) Ltd Opposition rejected
EP10824148A Mar, 2020 Teva Pharmaceutical Industries Ltd Opposition rejected
EP18155644A Feb, 2020 ARROW GENERIQUES Granted and Under Opposition
EP18155644A Feb, 2020 Teva Pharmaceutical Industries Ltd Granted and Under Opposition
EP18155644A Feb, 2020 Generics [UK] Limited Granted and Under Opposition
EP18155724A Feb, 2020 Ethypharm Granted and Under Opposition
EP18155644A Jan, 2020 Dr. Reddy's Laboratories Limited Granted and Under Opposition
EP18155724A Sep, 2019 BIOGARAN Granted and Under Opposition
EP18155644A Sep, 2019 Zentiva Pharma GmbH Granted and Under Opposition
EP16186041A Sep, 2019 STADA Arzneimittel AG Granted and Under Opposition
EP16186041A Sep, 2019 Generics [UK] Ltd Granted and Under Opposition
EP16186041A Sep, 2019 Accord Healthcare Ltd Granted and Under Opposition
EP16186041A Sep, 2019 Zentiva k.s. Granted and Under Opposition
EP16186041A Aug, 2019 Teva Pharmaceutical Industries Ltd Granted and Under Opposition
EP16186041A Aug, 2019 Synthon B.V. Granted and Under Opposition
EP18155724A Aug, 2019 Dr. Reddy's Laboratories / Betapharm Arzneimittel GmbH Granted and Under Opposition
EP18155724A Aug, 2019 Accord Healthcare Ltd Granted and Under Opposition
EP18155724A Aug, 2019 STADA Arzneimittel AG Granted and Under Opposition
EP18155644A Jul, 2019 Accord Healthcare Ltd Granted and Under Opposition
EP10174983A Jul, 2019 Zentiva France Revoked
EP18155644A Jul, 2019 Ethypharm Granted and Under Opposition
EP18155644A Jul, 2019 BIOGARAN Granted and Under Opposition
EP16186041A Jun, 2019 Ethypharm Granted and Under Opposition
EP18155644A May, 2019 STADA Arzneimittel AG Granted and Under Opposition
EP16167355A May, 2019 Teva Pharmaceutical Industries Ltd Opposition rejected
EP16167355A Apr, 2019 Generics (UK) Ltd Opposition rejected
EP04727320A Dec, 2018 Teva UK Limited Revoked
EP10181354A Dec, 2018 Teva UK Limited Patent maintained as amended
EP11806079A Apr, 2018 Generics (UK) Ltd Revoked
EP11806079A Apr, 2018 Teva Pharmaceutical Industries Ltd Revoked
EP14164259A Mar, 2018 Generics (UK) Ltd Revoked
EP15202422A Feb, 2018 actrevo GmbH Granted and Under Opposition
EP15202422A Feb, 2018 Generics [UK] Limited (trading as Mylan) Granted and Under Opposition
EP15202422A Feb, 2018 ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. Granted and Under Opposition
EP15202422A Feb, 2018 Bausch & Lomb Incorporated Granted and Under Opposition
EP15202422A Feb, 2018 Instone, Terry/Appleyard Lees IP LLP/Read, Howard Granted and Under Opposition
EP12193597A Jan, 2018 Generics [UK] Limited (trading as Mylan) Granted and Under Opposition
EP12193597A Jan, 2018 Alfred E. Tiefenbacher (GmbH & Co. KG) Granted and Under Opposition
EP14164565A Dec, 2017 Generics (U.K.) Limited Revoked
EP14164565A Dec, 2017 Ethypharm Revoked
EP06025389A Dec, 2017 Silence Therapeutics GmbH Revoked
EP10173956A Nov, 2017 D Young & Co LLP Patent maintained as amended
EP10174985A Apr, 2017 Intas Pharmaceuticals Ltd. Revoked
EP10174985A Apr, 2017 Generics [UK] Ltd Revoked
EP10174985A Apr, 2017 Wittkopp, Alexander Revoked
EP10174985A Apr, 2017 STADA Arzneimittel AG Revoked
EP10174985A Apr, 2017 Teva Pharmaceutical Industries Ltd Revoked
EP10174985A Apr, 2017 KRKA, d.d., Novo mesto Revoked
EP10174985A Apr, 2017 Fresenius Kabi Deutschland GmbH Revoked
EP10174985A Apr, 2017 Synthon Biopharmaceuticals B.V. Revoked
EP10011217A Apr, 2017 Silence Therapeutics GmbH Opposition rejected
EP09743378A Dec, 2016 STADA Arzneimittel AG Opposition rejected
EP10781781A Nov, 2016 Generics (U.K.) Limited Granted and Under Opposition
EP10781781A Nov, 2016 Hamm&Wittkopp Patentanwälte PartmbB Granted and Under Opposition
EP10781781A Nov, 2016 Teva Pharmaceutical Industries Ltd Granted and Under Opposition
EP10781781A Nov, 2016 Intas Pharmaceuticals Ltd. Granted and Under Opposition
EP10781781A Nov, 2016 Fresenius Kabi Deutschland GmbH Granted and Under Opposition
EP07840632A Sep, 2016 Galenicum Health S.L. Revoked
EP07840632A Sep, 2016 Generics (U.K.) Limited Revoked
EP07840632A Sep, 2016 Teva Pharmaceutical Industries Ltd Revoked
EP07840632A Sep, 2016 Alfred E. Tiefenbacher (GmbH & Co. KG) Revoked
EP07840632A Sep, 2016 ZBM Patents ApS Revoked
EP07820560A Jun, 2016 Fresenius Kabi Deutschland GmbH Patent maintained as amended
EP07820560A Jun, 2016 medac Gesellschaft für klinische Spezialpräparate mbH Patent maintained as amended
EP07820560A Jun, 2016 Strawman Limited Patent maintained as amended
EP07820560A Jun, 2016 Generics [UK] Limited Patent maintained as amended
EP12703670A Mar, 2016 Generics [UK] Limited Opposition rejected
EP12703670A Mar, 2016 I P S Intellectual Property Services Opposition rejected
EP12703670A Mar, 2016 Teva Pharmaceutical Industries Ltd Opposition rejected
EP09722278A Feb, 2016 Generics [UK] Limited (trading as Mylan) Granted and Under Opposition
EP10174983A Feb, 2016 STADA Arzneimittel AG Revoked
EP10174983A Feb, 2016 Actavis PTC ehf Revoked
EP10174983A Feb, 2016 Wittkopp, Alexander Revoked
EP10174983A Feb, 2016 Synthon B.V. Revoked
EP10174983A Feb, 2016 Intas Pharmaceuticals Ltd. Revoked
EP10174983A Feb, 2016 Generics [UK] Limited Revoked
EP10174983A Feb, 2016 Ethypharm Revoked
EP10174983A Feb, 2016 Teva Pharmaceutical Industries Ltd Revoked
EP09722278A Feb, 2016 Alfred E. Tiefenbacher (GmbH & Co. KG) Granted and Under Opposition
EP09722278A Feb, 2016 Pohlman, Sandra M. Granted and Under Opposition
EP10008929A Oct, 2015 Quark Pharmaceuticals, Inc. Patent maintained as amended
EP10175197A Jan, 2015 Maiwald Patentanwalts GmbH Revoked
EP10175197A Jan, 2015 Ethypharm Revoked
EP10175197A Jan, 2015 Generics [UK] Limited (trading as Mylan) Revoked
EP10175197A Jan, 2015 Synthon B.V./Genthon B.V. Revoked
EP10175197A Jan, 2015 Teva Pharmaceutical Industries Ltd. Revoked
EP06827689A Oct, 2014 Maiwald Patentanwalts GmbH Revoked
EP01935167A Jan, 2014 Taylor Wessing LLP Revoked
EP01935167A Jan, 2014 BIOGARAN Revoked
EP01935167A Jan, 2014 Accord Healthcare Ltd Revoked
EP01935167A Jan, 2014 Synthon B.V. Revoked
EP01935167A Jan, 2014 Sanovel IIaç San. ve Tic. A.S. Revoked
EP01935167A Dec, 2013 Genericon Pharma Gesellschaft m.b.H. Revoked
EP01935167A Nov, 2013 STADA Arzneimittel AG Revoked
EP01935167A Sep, 2013 PFIZER LIMITED Revoked
EP01935167A Sep, 2013 Hikma Pharma GmbH Revoked
EP01935167A Aug, 2013 Fresenius Kabi Deutschland GmbH Revoked
EP10008931A Jul, 2013 Alnylam Pharmaceuticals Inc. Opposition procedure closed
EP03716126A Jul, 2013 Alnylam Pharmaceuticals Inc. Opposition procedure closed
EP01935167A Jun, 2013 medac Gesellschaft für klinische Spezialpräparate mbH Revoked
EP01935167A Jun, 2013 Dr. Reddy's Laboratories Ltd. / Betapharm Arznei- mittel GmbH Revoked
EP10008930A May, 2013 Quark Pharmaceuticals, Inc. Patent maintained as amended
EP10008930A May, 2013 Alnylam Pharmaceuticals Inc. Patent maintained as amended
EP01935167A May, 2013 CHEMI SPA Revoked
EP01935167A May, 2013 Actavis Group Ptc Ehf Revoked
EP01935167A May, 2013 hameln rds gmbh Revoked
EP01935167A Apr, 2013 Teva Pharmaceutical Industries LTD. Revoked
EP01935167A Apr, 2013 Generics [UK] Limited Revoked
EP06800109A Mar, 2013 Actavis Group Ptc Ehf Revoked
EP06800109A Mar, 2013 D YOUNG & CO Revoked
EP04768542A Aug, 2012 Teva UK Limited Revoked
EP03743684A Jun, 2011 Alcon Research, Ltd. Patent maintained as amended
EP03743684A May, 2011 Dharmacon, Inc. Patent maintained as amended
EP03743684A May, 2011 Alnylam Pharmaceuticals Inc. Patent maintained as amended
EP03743684A May, 2011 Novartis AG Patent maintained as amended
EP03743684A May, 2011 Sanofi-Aventis Deutschland GmbH Patent maintained as amended
EP02702247A Dec, 2010 Sirna Therapeutics Revoked
EP02702247A Dec, 2010 Silence Therapeutics AG Revoked
EP03732397A Jan, 2010 Sanovel Ilac Sanayii ve Ticaret A.S. Revoked
EP03732397A Jan, 2010 KRKA, d.d., Novo mesto Revoked
EP03732397A Jan, 2010 Teva Pharmaceutical Industries Ltd. Revoked
EP03732397A Jan, 2010 Lupin Limited Revoked
EP05002454A Sep, 2009 Silence Therapeutics AG Granted and Under Opposition
EP05002454A Sep, 2009 ROQUES, Sarah Elizabeth Granted and Under Opposition
EP05002454A Sep, 2009 PFIZER LIMITED Granted and Under Opposition
EP05002454A Sep, 2009 Sanofi-Aventis Deutschland GmbH Granted and Under Opposition
EP05002454A Sep, 2009 Sirna Therapeutics Granted and Under Opposition
EP03704413A May, 2008 Mundipharma GmbH Opposition procedure closed
EP02710786A Feb, 2007 Sirna Therapeutics Opposition rejected
EP02003683A Mar, 2006 Abbott Laboratories Patent maintained as amended
EP02003683A Mar, 2006 atugen AG Patent maintained as amended
EP02003683A Mar, 2006 Quark Biotech, Inc. Patent maintained as amended
EP02003683A Mar, 2006 Sirna Therapeutics, Inc. Patent maintained as amended
EP00910510A May, 2003 AstraZeneca AB Revoked
EP00910510A May, 2003 Novartis AG Revoked
EP00910510A May, 2003 Isis Pharmaceuticals, Inc. Revoked
EP00910510A May, 2003 atugen AG Revoked
EP00910510A May, 2003 Aventis Pharma Deutschland GmbH Revoked
EP00910510A May, 2003 Grund, Martin, Dr. Revoked
EP00910510A May, 2003 JANSSEN PHARMACEUTICA N.V. Revoked
EP00910510A May, 2003 Sirna Therapeutics, Inc. Revoked


Novartis's Family Patents

Novartis drugs have patent protection in a total of 75 countries. It's US patent count contributes only to 29.7% of its total global patent coverage. 13 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Novartis Drug List

Given below is the complete list of Novartis's drugs and the patents protecting them.


1. Afinitor

Afinitor is protected by 14 patents, out of which 11 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9006224 Neuroendocrine tumor treatment 01 Jul, 2028
(3 years from now)
Active
US8410131
(Pediatric)
Cancer treatment 01 May, 2026
(1 year, 5 months from now)
Active
US8410131 Cancer treatment 01 Nov, 2025
(11 months from now)
Active
US8436010
(Pediatric)
Treatment of solid tumors with rapamycin derivatives 22 Aug, 2022
(2 years ago)
Expired
US8778962
(Pediatric)
Treatment of solid tumors with rapamycin derivatives 18 Aug, 2022
(2 years ago)
Expired
US8436010 Treatment of solid tumors with rapamycin derivatives 22 Feb, 2022
(2 years ago)
Expired
US8778962 Treatment of solid tumors with rapamycin derivatives 18 Feb, 2022
(2 years ago)
Expired
US7297703
(Pediatric)
Macrolides 06 Jun, 2020
(4 years ago)
Expired
US5665772
(Pediatric)
O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants 09 Mar, 2020
(4 years ago)
Expired
US7297703 Macrolides 06 Dec, 2019
(4 years ago)
Expired
US7741338 Macrolides 06 Dec, 2019
(4 years ago)
Expired
US5665772 O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants 09 Sep, 2019
(5 years ago)
Expired
US6004973
(Pediatric)
Pharmaceutical compositions comprising rafamycin coprecipitates 12 Jan, 2017
(7 years ago)
Expired
US6004973 Pharmaceutical compositions comprising rafamycin coprecipitates 12 Jul, 2016
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Afinitor's drug page


2. Alomide

Alomide is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5457126 Use of lodoxamide to treat ophthalmic allergic conditions 10 Oct, 2012
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Alomide's drug page


3. Amturnide

Amturnide is protected by 3 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8183295 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic 16 May, 2023
(1 year, 5 months ago)
Expired
US8618174 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases 15 Nov, 2021
(2 years ago)
Expired
US5559111 δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides 21 Jul, 2018
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Amturnide's drug page


4. Arcapta Neohaler

Arcapta Neohaler is protected by 5 patents, out of which 3 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8479730 Inhaler device 11 Oct, 2028
(3 years from now)
Active
US6878721 Beta2-adrenoceptor agonists 25 Feb, 2025
(3 months from now)
Active
US8067437 Beta-2-adrenoreceptor agonists 02 Jun, 2020
(4 years ago)
Expired
US8658673 BETA2-adrenoreceptor agonists 02 Jun, 2020
(4 years ago)
Expired
US8796307 Beta2-adrenoreceptor agonists 02 Jun, 2020
(4 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Arcapta Neohaler's drug page


5. Coartem

Coartem is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5677331 Antimalarial compositions 14 Oct, 2014
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Coartem's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Diovan

Diovan is protected by 5 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6294197
(Pediatric)
Solid oral dosage forms of valsartan 18 Dec, 2017
(6 years ago)
Expired
US6294197 Solid oral dosage forms of valsartan 18 Jun, 2017
(7 years ago)
Expired
US5972990
(Pediatric)
Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims 26 Apr, 2017
(7 years ago)
Expired
US5972990 Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims 26 Oct, 2016
(8 years ago)
Expired
US5399578
(Pediatric)
Acyl compounds 21 Sep, 2012
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Diovan's drug page


7. Diovan Hct

Diovan Hct is protected by 3 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6294197
(Pediatric)
Solid oral dosage forms of valsartan 18 Dec, 2017
(6 years ago)
Expired
US6294197 Solid oral dosage forms of valsartan 18 Jun, 2017
(7 years ago)
Expired
US5399578
(Pediatric)
Acyl compounds 21 Sep, 2012
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Diovan Hct's drug page


8. Emadine

Emadine is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5441958 Ophthalmic compositions comprising emedastine and methods for their use 08 Dec, 2013
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Emadine's drug page


9. Entresto Sprinkle

Entresto Sprinkle is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10722471 Galenic formulations of organic compounds 02 Feb, 2037
(12 years from now)
Active
US8877938 Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations 27 May, 2027
(2 years from now)
Active
US9388134 Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations 08 Nov, 2026
(1 year, 11 months from now)
Active
US8101659 Methods of treatment and pharmaceutical composition 15 Jan, 2025
(2 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Entresto Sprinkle's drug page


10. Exelon

Exelon is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5602176 Phenyl carbamate 11 Feb, 2014
(10 years ago)
Expired
US4948807 Phenyl carbamates 14 Aug, 2012
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Exelon's drug page


11. Exforge

Exforge is protected by 4 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6395728 Method of treatment and pharmaceutical composition 08 Jul, 2019
(5 years ago)
Expired
US6294197
(Pediatric)
Solid oral dosage forms of valsartan 18 Dec, 2017
(6 years ago)
Expired
US6294197 Solid oral dosage forms of valsartan 18 Jun, 2017
(7 years ago)
Expired
US5399578
(Pediatric)
Acyl compounds 21 Sep, 2012
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Exforge's drug page


12. Exforge Hct

Exforge Hct is protected by 6 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8475839
(Pediatric)
Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same 16 Nov, 2023
(11 months ago)
Expired
US8101599 Pharmaceutical composition containing anti-hypertensive agents 16 May, 2023
(1 year, 5 months ago)
Expired
US8475839 Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same 16 May, 2023
(1 year, 5 months ago)
Expired
US6294197
(Pediatric)
Solid oral dosage forms of valsartan 18 Dec, 2017
(6 years ago)
Expired
US6294197 Solid oral dosage forms of valsartan 18 Jun, 2017
(7 years ago)
Expired
US5399578
(Pediatric)
Acyl compounds 21 Sep, 2012
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Exforge Hct's drug page


13. Exjade

Exjade is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6465504 Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators 05 Apr, 2019
(5 years ago)
Expired
US6596750 Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators 24 Jun, 2017
(7 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Exjade's drug page


14. Fabhalta

Fabhalta is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11951101 Methods of using factor B inhibitors 15 Jul, 2041
(16 years from now)
Active
US11603363 Crystalline form of LNP023 25 May, 2041
(16 years from now)
Active
US11723901 Uses of piperidinyl-indole derivatives 30 Aug, 2038
(13 years from now)
Active
US10093663 Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof 14 Jul, 2034
(9 years from now)
Active
US9682968 Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof 14 Jul, 2034
(9 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fabhalta's drug page


15. Famvir

Famvir is protected by 8 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5840763
(Pediatric)
Treatment of a latent infection of herpes viruses 01 Mar, 2016
(8 years ago)
Expired
US5916893
(Pediatric)
Treatment of a latent infection of herpes virus 01 Mar, 2016
(8 years ago)
Expired
US5840763 Treatment of a latent infection of herpes viruses 01 Sep, 2015
(9 years ago)
Expired
US5916893 Treatment of a latent infection of herpes virus 01 Sep, 2015
(9 years ago)
Expired
US5866581
(Pediatric)
Penciclovir for the treatment of post therapeutic neuralgia 04 Apr, 2015
(9 years ago)
Expired
US6124304
(Pediatric)
Penciclovir for the treatment of zoster associated pain 04 Apr, 2015
(9 years ago)
Expired
US5866581 Penciclovir for the treatment of post therapeutic neuralgia 04 Oct, 2014
(10 years ago)
Expired
US6124304 Penciclovir for the treatment of zoster associated pain 04 Oct, 2014
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Famvir's drug page


16. Foradil

Foradil is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6887459 Aerosol composition comprising formoterol 28 Nov, 2020
(3 years ago)
Expired
US6488027 Powder inhaler 08 Mar, 2019
(5 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Foradil's drug page


17. Gilenya

Gilenya is protected by 11 patents, out of which 4 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9592208
(Pediatric)
Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol 30 Sep, 2032
(7 years from now)
Active
US9592208 Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol 30 Mar, 2032
(7 years from now)
Active
US10543179 Dosage regimen of an S1P receptor modulator 25 Dec, 2027
(3 years from now)
Active
US9187405
(Pediatric)
S1P receptor modulators for treating relasping-remitting multiple sclerosis 25 Dec, 2027
(3 years from now)
Active
US9187405 S1P receptor modulators for treating relasping-remitting multiple sclerosis 25 Jun, 2027
(2 years from now)
Active
US8324283
(Pediatric)
Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol 29 Sep, 2026
(1 year, 10 months from now)
Active
US8324283 Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol 29 Mar, 2026
(1 year, 4 months from now)
Active
US5604229
(Pediatric)
2-amino-1,3-propanediol compound and immunosuppressant 18 Aug, 2019
(5 years ago)
Expired
US5604229 2-amino-1,3-propanediol compound and immunosuppressant 18 Feb, 2019
(5 years ago)
Expired
US6004565 Compositions and methods of using compositions with accelerated lymphocyte homing immunosuppressive properties 23 Sep, 2017
(7 years ago)
Expired
US5604229 2-amino-1,3-propanediol compound and immunosuppressant 18 Feb, 2014
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Gilenya's drug page


18. Gleevec

Gleevec is protected by 12 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6958335
(Pediatric)
Treatment of gastrointestinal stromal tumors 19 Jun, 2022
(2 years ago)
Expired
US6958335 Treatment of gastrointestinal stromal tumors 19 Dec, 2021
(2 years ago)
Expired
US6894051
(Pediatric)
Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use 23 Nov, 2019
(4 years ago)
Expired
US7544799
(Pediatric)
Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use 16 Jul, 2019
(5 years ago)
Expired
USRE43932
(Pediatric)
Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use 16 Jul, 2019
(5 years ago)
Expired
US6894051 Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use 23 May, 2019
(5 years ago)
Expired
US7544799 Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use 16 Jan, 2019
(5 years ago)
Expired
USRE43932 Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use 16 Jan, 2019
(5 years ago)
Expired
USRE43932
(Pediatric)
Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use 16 Jan, 2019
(5 years ago)
Expired
USRE43932 Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use 16 Jul, 2018
(6 years ago)
Expired
US5521184
(Pediatric)
Pyrimidine derivatives and processes for the preparation thereof 04 Jul, 2015
(9 years ago)
Expired
US5521184 Pyrimidine derivatives and processes for the preparation thereof 04 Jan, 2015
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Gleevec's drug page


19. Izba

Izba is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8178582 Pharmaceutical compositions having desirable bioavailability 10 Oct, 2029
(4 years from now)
Active
US8722735 Pharmaceutical compositions having desirable bioavailability 10 Oct, 2029
(4 years from now)
Active
US8754123 Pharmaceutical compositions having desirable bioavailability 19 May, 2029
(4 years from now)
Active
US9144561 Pharmaceutical compositions having desirable bioavailability 13 Mar, 2029
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Izba's drug page


20. Jadenu Sprinkle

Jadenu Sprinkle is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6465504 Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators 05 Apr, 2019
(5 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Jadenu Sprinkle's drug page


21. Kisqali

Kisqali is protected by 9 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10799506 Ribociclib tablet 14 Apr, 2036
(11 years from now)
Active
US12064434 Ribociclib tablet 14 Apr, 2036
(11 years from now)
Active
US9193732 Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof 09 Nov, 2031
(6 years from now)
Active
US9868739 Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof 09 Nov, 2031
(6 years from now)
Active
US8415355 Pyrrolopyrimidine compounds and their uses 13 Mar, 2031
(6 years from now)
Active
US8685980 Pyrrolopyrimidine compounds and their uses 25 May, 2030
(5 years from now)
Active
US8962630 Pyrrolopyrimidine compounds and their uses 09 Dec, 2029
(5 years from now)
Active
US9416136 Pyrrolopyrimidine compounds and their uses 20 Aug, 2029
(4 years from now)
Active
US8324225 Pyrrolopyrimidine compounds and their uses 17 Jun, 2028
(3 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kisqali's drug page


22. Kisqali Femara Co-pack (copackaged)

Kisqali Femara Co-pack (copackaged) is protected by 9 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10799506 Ribociclib tablet 14 Apr, 2036
(11 years from now)
Active
US12064434 Ribociclib tablet 14 Apr, 2036
(11 years from now)
Active
US9193732 Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof 09 Nov, 2031
(6 years from now)
Active
US9868739 Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof 09 Nov, 2031
(6 years from now)
Active
US8415355 Pyrrolopyrimidine compounds and their uses 13 Mar, 2031
(6 years from now)
Active
US8685980 Pyrrolopyrimidine compounds and their uses 25 May, 2030
(5 years from now)
Active
US8962630 Pyrrolopyrimidine compounds and their uses 09 Dec, 2029
(5 years from now)
Active
US9416136 Pyrrolopyrimidine compounds and their uses 20 Aug, 2029
(4 years from now)
Active
US8324225 Pyrrolopyrimidine compounds and their uses 17 Jun, 2028
(3 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kisqali Femara Co-pack (copackaged)'s drug page


23. Leqvio

Leqvio is protected by 20 patents, out of which 11 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10851377 Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder 25 Aug, 2036
(11 years from now)
Active
US10125369 PCSK9 iRNA compositions and methods of use thereof 18 Aug, 2034
(9 years from now)
Active
US8106022 Carbohydrate conjugates as delivery agents for oligonucleotides 12 Dec, 2029
(5 years from now)
Active
US10806791 Carbohydrate conjugates as delivery agents for oligonucleotides 04 Dec, 2028
(4 years from now)
Active
US8828956 Carbohydrate conjugates as delivery agents for oligonucleotides 04 Dec, 2028
(4 years from now)
Active
US9370582 Carbohydrate conjugates as delivery agents for oligonucleotides 04 Dec, 2028
(4 years from now)
Active
US10131907 Glycoconjugates of RNA interference agents 24 Aug, 2028
(3 years from now)
Active
US8222222 Compositions and methods for inhibiting expression of the PCSK9 gene 29 Dec, 2027
(3 years from now)
Active
US8809292 Compositions and methods for inhibiting expression of the PCSK9 gene 10 May, 2027
(2 years from now)
Active
US11530408 Therapeutic compositions 18 May, 2024
(5 months ago)
Expired
US10273477 Therapeutic compositions 08 Mar, 2024
(8 months ago)
Expired
US10669544 Therapeutic compositions 08 Mar, 2024
(8 months ago)
Expired
US9708615 Therapeutic compositions 08 Mar, 2024
(8 months ago)
Expired
US9708610 Compositions comprising alternating 2′-modified nucleosides for use in gene modulation 01 Jan, 2024
(10 months ago)
Expired
US10266825 Compositions comprising alternating 2′-modified nucleosides for use in gene modulation 04 Nov, 2023
(1 year, 7 days ago)
Expired
US11078485 Compositions comprising alternating 2′-modified nucleosides for use in gene modulation 04 Nov, 2023
(1 year, 7 days ago)
Expired
US8232383 RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) 20 Feb, 2023
(1 year, 8 months ago)
Expired
US10590418 Methods and compositions for RNAi mediated inhibition of gene expression in mammals 19 Jul, 2022
(2 years ago)
Expired
US8546143 Compositions and methods for inhibiting expression of a target gene 23 Apr, 2022
(2 years ago)
Expired
US9074213 Compositions and methods for inhibiting expression of a target gene 09 Mar, 2022
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Leqvio's drug page


24. Locametz

Locametz is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12109277 09 Mar, 2036
(11 years from now)
Active
US11369590 PSMA binding ligand-linker conjugates and methods for using 15 Aug, 2028
(3 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Locametz's drug page


25. Mayzent

Mayzent is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11944602 Treatment of autoimmune disease in a patient receiving additionally a beta-blocker 24 Jul, 2036
(11 years from now)
Active
US12071402 Immunosuppressant formulations 05 Jan, 2032
(7 years from now)
Active
US8492441 Dosage regimen of an S1P receptor agonist 30 Nov, 2030
(6 years from now)
Active
US7939519 Immunosuppresant compounds and compositions 27 Aug, 2028
(3 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mayzent's drug page


26. Mekinist

Mekinist is protected by 18 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10869869
(Pediatric)
Method of adjuvant cancer treatment 02 Mar, 2034
(9 years from now)
Active
US10869869 Method of adjuvant cancer treatment 30 Aug, 2033
(8 years from now)
Active
US8580304
(Pediatric)
Pharmaceutical composition 28 Jul, 2032
(7 years from now)
Active
US9155706
(Pediatric)
Pharmaceutical composition 28 Jul, 2032
(7 years from now)
Active
US9271941
(Pediatric)
Pharmaceutical composition 28 Jul, 2032
(7 years from now)
Active
US9399021
(Pediatric)
Pharmaceutical composition 28 Jul, 2032
(7 years from now)
Active
US8580304 Pharmaceutical composition 28 Jan, 2032
(7 years from now)
Active
US9155706 Pharmaceutical composition 28 Jan, 2032
(7 years from now)
Active
US9271941 Pharmaceutical composition 28 Jan, 2032
(7 years from now)
Active
US9399021 Pharmaceutical composition 28 Jan, 2032
(7 years from now)
Active
US8703781
(Pediatric)
Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors 15 Apr, 2031
(6 years from now)
Active
US8952018
(Pediatric)
Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors 15 Apr, 2031
(6 years from now)
Active
US8703781 Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors 15 Oct, 2030
(5 years from now)
Active
US8952018 Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors 15 Oct, 2030
(5 years from now)
Active
US7378423
(Pediatric)
Pyrimidine compound and medical use thereof 29 Nov, 2027
(3 years from now)
Active
US7378423 Pyrimidine compound and medical use thereof 29 May, 2027
(2 years from now)
Active
US8835443
(Pediatric)
Pyrimidine compound and medical use thereof 10 Dec, 2025
(1 year, 29 days from now)
Active
US8835443 Pyrimidine compound and medical use thereof 10 Jun, 2025
(6 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mekinist's drug page


27. Myfortic

Myfortic is protected by 3 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6306900 Enteric coated pharmaceutical compositions 27 Feb, 2018
(6 years ago)
Expired
US6025391 Enteric-coated pharmaceutical compositions of mycophenolate 10 Apr, 2017
(7 years ago)
Expired
US6172107 Entric-coated pharmaceutical compositions 10 Apr, 2017
(7 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Myfortic's drug page


28. Neoral

Neoral is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5985321 Soft gelatin capsule manufacture 26 Sep, 2014
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Neoral's drug page


29. Patanase

Patanase is protected by 4 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7977376
(Pediatric)
Olopatadine formulations for topical nasal administration 02 Aug, 2023
(1 year, 3 months ago)
Expired
US8399508
(Pediatric)
Olopatadine formulations for topical nasal administration 17 Mar, 2023
(1 year, 7 months ago)
Expired
US7977376 Olopatadine formulations for topical nasal administration 02 Feb, 2023
(1 year, 9 months ago)
Expired
US8399508 Olopatadine formulations for topical nasal administration 17 Sep, 2022
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Patanase's drug page


30. Piqray

Piqray is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8227462 Pyrrolidine-1,2-dicarboxamide derivatives 29 Apr, 2033
(8 years from now)
Active
US8476268 Pyrrolidine-1,2-dicarboxamide derivatives 10 Sep, 2029
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Piqray's drug page


31. Pluvicto

Pluvicto is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11951190 Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer 12 Nov, 2035
(11 years from now)
Active
US10398791 Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer 17 Oct, 2034
(9 years from now)
Active
US10406240 PSMA binding ligand-linker conjugates and methods for using 15 Aug, 2028
(3 years from now)
Active
US11318121 PSMA binding ligand-linker conjugates and methods for using 15 Aug, 2028
(3 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pluvicto's drug page


32. Promacta

Promacta is protected by 28 patents, out of which 14 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8052993
(Pediatric)
3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) 01 Feb, 2028
(3 years from now)
Active
US8052994
(Pediatric)
3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) 01 Feb, 2028
(3 years from now)
Active
US8052995
(Pediatric)
3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) 01 Feb, 2028
(3 years from now)
Active
US8062665
(Pediatric)
3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) 01 Feb, 2028
(3 years from now)
Active
US8071129
(Pediatric)
3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) 01 Feb, 2028
(3 years from now)
Active
US8828430
(Pediatric)
3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) 01 Feb, 2028
(3 years from now)
Active
US8052993 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) 01 Aug, 2027
(2 years from now)
Active
US8052994 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) 01 Aug, 2027
(2 years from now)
Active
US8052995 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) 01 Aug, 2027
(2 years from now)
Active
US8062665 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) 01 Aug, 2027
(2 years from now)
Active
US8071129 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) 01 Aug, 2027
(2 years from now)
Active
US8828430 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) 01 Aug, 2027
(2 years from now)
Active
US7547719
(Pediatric)
3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) 13 Jan, 2026
(1 year, 2 months from now)
Active
US7547719 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) 13 Jul, 2025
(8 months from now)
Active
US7795293
(Pediatric)
3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) 21 Nov, 2023
(11 months ago)
Expired
US7795293 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) 21 May, 2023
(1 year, 5 months ago)
Expired
US7160870
(Pediatric)
Thrombopoietin mimetics 20 May, 2023
(1 year, 5 months ago)
Expired
US7160870 Thrombopoietin mimetics 20 Nov, 2022
(1 year, 11 months ago)
Expired
US7332481
(Pediatric)
Thrombopoietin mimetics 24 Nov, 2021
(2 years ago)
Expired
US7452874
(Pediatric)
Thrombopoietin mimetics 24 Nov, 2021
(2 years ago)
Expired
US7473686
(Pediatric)
Thrombopoietin mimetics 24 Nov, 2021
(2 years ago)
Expired
US7790704
(Pediatric)
Thrombopoietin mimetics 24 Nov, 2021
(2 years ago)
Expired
US7332481 Thrombopoietin mimetics 24 May, 2021
(3 years ago)
Expired
US7452874 Thrombopoietin mimetics 24 May, 2021
(3 years ago)
Expired
US7473686 Thrombopoietin mimetics 24 May, 2021
(3 years ago)
Expired
US7790704 Thrombopoietin mimetics 24 May, 2021
(3 years ago)
Expired
US6280959
(Pediatric)
Metal complexes 30 Apr, 2019
(5 years ago)
Expired
US6280959 Metal complexes 30 Oct, 2018
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Promacta's drug page


33. Promacta Kit

Promacta Kit is protected by 16 patents, out of which 14 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7547719
(Pediatric)
3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) 13 Jan, 2026
(1 year, 2 months from now)
Active
US7547719 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) 13 Jul, 2025
(8 months from now)
Active
US7795293
(Pediatric)
3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) 21 Nov, 2023
(11 months ago)
Expired
US7795293 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) 21 May, 2023
(1 year, 5 months ago)
Expired
US7160870
(Pediatric)
Thrombopoietin mimetics 20 May, 2023
(1 year, 5 months ago)
Expired
US7160870 Thrombopoietin mimetics 20 Nov, 2022
(1 year, 11 months ago)
Expired
US7332481
(Pediatric)
Thrombopoietin mimetics 24 Nov, 2021
(2 years ago)
Expired
US7452874
(Pediatric)
Thrombopoietin mimetics 24 Nov, 2021
(2 years ago)
Expired
US7473686
(Pediatric)
Thrombopoietin mimetics 24 Nov, 2021
(2 years ago)
Expired
US7790704
(Pediatric)
Thrombopoietin mimetics 24 Nov, 2021
(2 years ago)
Expired
US7332481 Thrombopoietin mimetics 24 May, 2021
(3 years ago)
Expired
US7452874 Thrombopoietin mimetics 24 May, 2021
(3 years ago)
Expired
US7473686 Thrombopoietin mimetics 24 May, 2021
(3 years ago)
Expired
US7790704 Thrombopoietin mimetics 24 May, 2021
(3 years ago)
Expired
US6280959
(Pediatric)
Metal complexes 30 Apr, 2019
(5 years ago)
Expired
US6280959 Metal complexes 30 Oct, 2018
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Promacta Kit's drug page


34. Rydapt

Rydapt is protected by 3 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8575146 Pharmaceutical uses of staurosporine derivatives 02 Dec, 2030
(6 years from now)
Active
US7973031 Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity 09 Oct, 2028
(3 years from now)
Active
US8222244 Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity 29 Oct, 2022
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rydapt's drug page


35. Sandostatin

Sandostatin is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5753618
(Pediatric)
Somatostatin analogue composition and use in treating breast cancer 19 Nov, 2015
(8 years ago)
Expired
US5753618 Somatostatin analogue composition and use in treating breast cancer 19 May, 2015
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sandostatin's drug page


36. Sandostatin Lar

Sandostatin Lar is protected by 10 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5922338
(Pediatric)
Polyol esters, their preparation and use in depot forms of pharmacologically active agents 13 Jan, 2017
(7 years ago)
Expired
US5922682
(Pediatric)
Polyol esters, their preparation and use in depot forms of pharmacologically active agents 13 Jan, 2017
(7 years ago)
Expired
US5922338 Polyol esters, their preparation and use in depot forms of pharmacologically active agents 13 Jul, 2016
(8 years ago)
Expired
US5922682 Polyol esters, their preparation and use in depot forms of pharmacologically active agents 13 Jul, 2016
(8 years ago)
Expired
US5688530
(Pediatric)
Sustained release formulations of water soluble peptides 18 May, 2015
(9 years ago)
Expired
US5639480
(Pediatric)
Sustained release formulations of water soluble peptides 17 Dec, 2014
(9 years ago)
Expired
US5688530 Sustained release formulations of water soluble peptides 18 Nov, 2014
(9 years ago)
Expired
US5639480 Sustained release formulations of water soluble peptides 17 Jun, 2014
(10 years ago)
Expired
US5538739
(Pediatric)
Sustained release formulations of water soluble peptides 23 Jan, 2014
(10 years ago)
Expired
US5538739 Sustained release formulations of water soluble peptides 23 Jul, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sandostatin Lar's drug page


37. Scemblix

Scemblix is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11407735 Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide 14 May, 2040
(15 years from now)
Active
US8829195 Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 13 May, 2033
(8 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Scemblix's drug page


38. Seebri

Seebri is protected by 15 patents, out of which 13 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8182838 Dry powder composition comprising co-jet milled particles for pulmonary inhalation 20 Oct, 2028
(3 years from now)
Active
US8479730 Inhaler device 11 Oct, 2028
(3 years from now)
Active
US7736670 Method of making particles for use in a pharmaceutical composition 27 Jun, 2021
(3 years ago)
Expired
US8048451 Pharmaceutical compositions for inhalation 27 Jun, 2021
(3 years ago)
Expired
US8303991 Method of making particles for use in a pharmaceutical composition 27 Jun, 2021
(3 years ago)
Expired
US8435567 Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation 27 Jun, 2021
(3 years ago)
Expired
US8580306 Particles for use in a pharmaceutical composition 27 Jun, 2021
(3 years ago)
Expired
US8956661 Method of making composite particles for use in pharmaceutical compositions and composite particles and compositions thereof 27 Jun, 2021
(3 years ago)
Expired
US9931304 Method of making particles for use in a pharmaceutical composition 27 Jun, 2021
(3 years ago)
Expired
US9962338 Method of making particles for use in a pharmaceutical composition 27 Jun, 2021
(3 years ago)
Expired
US7229607 Treatment of respiratory disease 09 Apr, 2021
(3 years ago)
Expired
US8029768 Treatment of respiratory diseases 09 Apr, 2021
(3 years ago)
Expired
US6528678 Phosgene-free process for preparing carbamates 24 Apr, 2018
(6 years ago)
Expired
US6582678 Carrier particles for use in dry powder inhalers 24 Apr, 2018
(6 years ago)
Expired
US6521260 Carrier particles for use in dry powder inhalers 31 Jan, 2016
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Seebri's drug page


39. Starlix

Starlix is protected by 6 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6559188 Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes 15 Sep, 2020
(4 years ago)
Expired
US6878749 Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes 15 Sep, 2020
(4 years ago)
Expired
US6641841 Tablet composition 14 Nov, 2017
(6 years ago)
Expired
US6844008 Tablet composition 14 Nov, 2017
(6 years ago)
Expired
US5488150 Crystals of N-(trans-4-isopropylcyclohexycarbonyl)-D-phenylalanine and methods for preparing them 30 Jan, 2013
(11 years ago)
Expired
US5463116 Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them 21 Oct, 2012
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Starlix's drug page


40. Tafinlar

Tafinlar is protected by 16 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11504333
(Pediatric)
Pharmaceutical composition 29 Dec, 2038
(14 years from now)
Active
US11504333 Pharmaceutical composition 29 Jun, 2038
(13 years from now)
Active
US10869869
(Pediatric)
Method of adjuvant cancer treatment 02 Mar, 2034
(9 years from now)
Active
US10869869 Method of adjuvant cancer treatment 30 Aug, 2033
(8 years from now)
Active
US8703781
(Pediatric)
Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors 15 Apr, 2031
(6 years from now)
Active
US8952018
(Pediatric)
Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors 15 Apr, 2031
(6 years from now)
Active
US8703781 Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors 15 Oct, 2030
(5 years from now)
Active
US8952018 Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors 15 Oct, 2030
(5 years from now)
Active
US7994185
(Pediatric)
Benzene sulfonamide thiazole and oxazole compounds 20 Jul, 2030
(5 years from now)
Active
US8415345
(Pediatric)
Benzene sulfonamide thiazole and oxazole compounds 20 Jul, 2030
(5 years from now)
Active
US7994185 Benzene sulfonamide thiazole and oxazole compounds 20 Jan, 2030
(5 years from now)
Active
US8415345 Benzene sulfonamide thiazole and oxazole compounds 20 Jan, 2030
(5 years from now)
Active
US9233956
(Pediatric)
Benzene sulfonamide thiazole and oxazole compounds 04 Nov, 2029
(4 years from now)
Active
US9233956 Benzene sulfonamide thiazole and oxazole compounds 04 May, 2029
(4 years from now)
Active
US8835443
(Pediatric)
Pyrimidine compound and medical use thereof 10 Dec, 2025
(1 year, 29 days from now)
Active
US8835443 Pyrimidine compound and medical use thereof 10 Jun, 2025
(6 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tafinlar's drug page


41. Tasigna

Tasigna is protected by 14 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9061029
(Pediatric)
Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity 07 Oct, 2032
(7 years from now)
Active
US9061029 Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity 07 Apr, 2032
(7 years from now)
Active
US8163904
(Pediatric)
Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide 23 Feb, 2029
(4 years from now)
Active
US8163904 Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide 23 Aug, 2028
(3 years from now)
Active
US8293756
(Pediatric)
Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate 25 Mar, 2028
(3 years from now)
Active
US8293756 Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate 25 Sep, 2027
(2 years from now)
Active
US8389537
(Pediatric)
Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide 18 Jan, 2027
(2 years from now)
Active
US8415363
(Pediatric)
Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide 18 Jan, 2027
(2 years from now)
Active
US8501760
(Pediatric)
Pharmaceutical compositions comprising nilotinib or its salt 18 Jan, 2027
(2 years from now)
Active
US8389537 Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide 18 Jul, 2026
(1 year, 8 months from now)
Active
US8415363 Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide 18 Jul, 2026
(1 year, 8 months from now)
Active
US8501760 Pharmaceutical compositions comprising nilotinib or its salt 18 Jul, 2026
(1 year, 8 months from now)
Active
US7169791
(Pediatric)
Inhibitors of tyrosine kinases 04 Jan, 2024
(10 months ago)
Expired
US7169791 Inhibitors of tyrosine kinases 04 Jul, 2023
(1 year, 4 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tasigna's drug page


42. Tekamlo

Tekamlo is protected by 2 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8613949 Galenical formulations of organic compounds 21 Dec, 2029
(5 years from now)
Active
US5559111 δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides 21 Jul, 2018
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tekamlo's drug page


43. Trileptal

Trileptal is protected by 4 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8119148
(Pediatric)
Suspension comprising oxcarbazepine 19 Jun, 2021
(3 years ago)
Expired
US8119148 Suspension comprising oxcarbazepine 19 Dec, 2020
(3 years ago)
Expired
US7037525
(Pediatric)
Oxacarbazepine film-coated tablets 12 Aug, 2018
(6 years ago)
Expired
US7037525 Oxacarbazepine film-coated tablets 12 Feb, 2018
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Trileptal's drug page


44. Tykerb

Tykerb is protected by 7 patents, out of which 6 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8821927 Pharmaceutical composition 18 Sep, 2029
(4 years from now)
Active
US7157466 Quinazoline ditosylate salt compounds 19 Nov, 2021
(2 years ago)
Expired
US6713485 Heterocyclic compounds 29 Sep, 2020
(4 years ago)
Expired
US6727256 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors 08 Jan, 2019
(5 years ago)
Expired
US8513262 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors 08 Jan, 2019
(5 years ago)
Expired
US6391874 Fused heterocyclic compounds as protein tyrosine kinase inhibitors 11 Jul, 2017
(7 years ago)
Expired
US6828320 Heterocyclic compounds 11 Jul, 2017
(7 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tykerb's drug page


45. Tyzeka

Tyzeka is protected by 7 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7589079 Crystalline and amorphous forms of beta-L-2′-deoxythymidine 11 Sep, 2023
(1 year, 2 months ago)
Expired
US7858594 Crystalline and amorphous forms of beta-L-2′-deoxythymidine 11 Sep, 2023
(1 year, 2 months ago)
Expired
US6569837 β-L-2′-deoxy pyrimidine nucleosides for the treatment of hepatitis B 25 Oct, 2020
(4 years ago)
Expired
US6395716 β-L-2′-deoxy-nucleosides for the treatment of hepatitis B 10 Aug, 2019
(5 years ago)
Expired
US6444652 β-L-2'-deoxy-nucleosides for the treatment of hepatitis B 10 Aug, 2019
(5 years ago)
Expired
US6566344 β-L-2′-deoxy-nucleosides for the treatment of hepatitis B 10 Aug, 2019
(5 years ago)
Expired
US7795238 β-L-2′-deoxy-nucleosides for the treatment of hepatitis B 10 Aug, 2019
(5 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tyzeka's drug page


46. Utibron

Utibron is protected by 20 patents, out of which 17 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8182838 Dry powder composition comprising co-jet milled particles for pulmonary inhalation 20 Oct, 2028
(3 years from now)
Active
US8479730 Inhaler device 11 Oct, 2028
(3 years from now)
Active
US6878721 Beta2-adrenoceptor agonists 25 Feb, 2025
(3 months from now)
Active
US7736670 Method of making particles for use in a pharmaceutical composition 27 Jun, 2021
(3 years ago)
Expired
US8048451 Pharmaceutical compositions for inhalation 27 Jun, 2021
(3 years ago)
Expired
US8303991 Method of making particles for use in a pharmaceutical composition 27 Jun, 2021
(3 years ago)
Expired
US8435567 Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation 27 Jun, 2021
(3 years ago)
Expired
US8580306 Particles for use in a pharmaceutical composition 27 Jun, 2021
(3 years ago)
Expired
US8956661 Method of making composite particles for use in pharmaceutical compositions and composite particles and compositions thereof 27 Jun, 2021
(3 years ago)
Expired
US9931304 Method of making particles for use in a pharmaceutical composition 27 Jun, 2021
(3 years ago)
Expired
US9962338 Method of making particles for use in a pharmaceutical composition 27 Jun, 2021
(3 years ago)
Expired
US7229607 Treatment of respiratory disease 09 Apr, 2021
(3 years ago)
Expired
US8029768 Treatment of respiratory diseases 09 Apr, 2021
(3 years ago)
Expired
US7820694 Beta-2-adrenoreceptor agonists 02 Jun, 2020
(4 years ago)
Expired
US8067437 Beta-2-adrenoreceptor agonists 02 Jun, 2020
(4 years ago)
Expired
US8283362 Beta-2-adrenoreceptor agonists 02 Jun, 2020
(4 years ago)
Expired
US8658673 BETA2-adrenoreceptor agonists 02 Jun, 2020
(4 years ago)
Expired
US8796307 Beta2-adrenoreceptor agonists 02 Jun, 2020
(4 years ago)
Expired
US6582678 Carrier particles for use in dry powder inhalers 24 Apr, 2018
(6 years ago)
Expired
US6521260 Carrier particles for use in dry powder inhalers 31 Jan, 2016
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Utibron's drug page


47. Valturna

Valturna is protected by 2 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8168616 Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension 03 Jul, 2026
(1 year, 7 months from now)
Active
US5559111 δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides 21 Jul, 2018
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Valturna's drug page


48. Vijoice

Vijoice is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8227462 Pyrrolidine-1,2-dicarboxamide derivatives 29 Apr, 2033
(8 years from now)
Active
US8476268 Pyrrolidine-1,2-dicarboxamide derivatives 10 Sep, 2029
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vijoice's drug page


49. Vitravene Preservative Free

Vitravene Preservative Free is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5442049 Oligonucleotides for modulating the effects of cytomegalovirus infections 15 Aug, 2012
(12 years ago)
Expired
US5595978 Composition and method for treatment of CMV retinites 15 Aug, 2012
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vitravene Preservative Free's drug page


50. Votrient

Votrient is protected by 3 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7105530 Pyrimidineamines as angiogenesis modulators 19 Oct, 2023
(1 year, 23 days ago)
Expired
US7262203 Pyrimidineamines as angiogenesis modulators 19 Dec, 2021
(2 years ago)
Expired
US8114885 Chemical compounds 19 Dec, 2021
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Votrient's drug page


51. Zometa

Zometa is protected by 5 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7932241 Pharmaceutical products comprising bisphosphonates 05 Feb, 2028
(3 years from now)
Active
US8324189
(Pediatric)
Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases 29 Nov, 2025
(1 year, 18 days from now)
Active
US8324189 Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases 29 May, 2025
(6 months from now)
Active
US4939130
(Pediatric)
Substituted alkanediphosphonic acids and pharmaceutical use 02 Mar, 2013
(11 years ago)
Expired
US4939130 Substituted alkanediphosphonic acids and pharmaceutical use 02 Sep, 2012
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zometa's drug page


52. Zortress

Zortress is protected by 10 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5665772
(Pediatric)
O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants 09 Mar, 2020
(4 years ago)
Expired
US5665772 O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants 09 Sep, 2019
(5 years ago)
Expired
US6239124
(Pediatric)
Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin 11 Feb, 2018
(6 years ago)
Expired
US6455518
(Pediatric)
Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin 29 Jan, 2018
(6 years ago)
Expired
US6239124 Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin 11 Aug, 2017
(7 years ago)
Expired
US6455518 Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin 29 Jul, 2017
(7 years ago)
Expired
US6004973
(Pediatric)
Pharmaceutical compositions comprising rafamycin coprecipitates 12 Jan, 2017
(7 years ago)
Expired
US6004973 Pharmaceutical compositions comprising rafamycin coprecipitates 12 Jul, 2016
(8 years ago)
Expired
US6440990
(Pediatric)
O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants 24 Mar, 2014
(10 years ago)
Expired
US6440990 O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants 24 Sep, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zortress's drug page


53. Zykadia

Zykadia is protected by 13 patents, out of which 5 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8703787 Methods of using ALK inhibitors 02 Feb, 2032
(7 years from now)
Active
US9309229 Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine 18 Jan, 2032
(7 years from now)
Active
US8039474 2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists 29 Jun, 2030
(5 years from now)
Active
US8039479 Compounds and compositions as protein kinase inhibitors 29 Jun, 2030
(5 years from now)
Active
US7964592 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders 29 Apr, 2028
(3 years from now)
Active
US8377921 Compounds and compositions as protein kinase inhibitors 20 Nov, 2027
(3 years from now)
Active
US8399450 Compounds and compositions as protein kinase inhibitors 20 Nov, 2027
(3 years from now)
Active
US7893074 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders 25 Apr, 2026
(1 year, 5 months from now)
Active
US8188276 2,4-pyrimidinediamine compounds and their uses 31 Jan, 2023
(1 year, 9 months ago)
Expired
US8835430 2,4-pyrimidinediamine compounds and their uses 31 Jan, 2023
(1 year, 9 months ago)
Expired
US9018204 2,4-pyrimidinediamine compounds and their uses 31 Jan, 2023
(1 year, 9 months ago)
Expired
US9416112 2,4-pyrimidinediamine compounds and their uses 31 Jan, 2023
(1 year, 9 months ago)
Expired
US7153964 Pyrimidine compounds 26 Feb, 2021
(3 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zykadia's drug page


Novartis News

Judge Rules FDA can authorize more affordable generic version of heart-failure medication Entresto

17 Oct, 2024

Novartis fails to prevent generic version of popular heart medication - HealthLeaders

17 Oct, 2024

Novartis fails in attempt to prevent generic version of popular heart medication

16 Oct, 2024

The US Department of Health and Human Services announces cost savings for 54 prescription medications, including Novartis' cancer treatment...

01 Oct, 2024

See More